News

Under the deal, the data will also be used to inform target selection, target validation, indication selection and repositioning. The deal will see Genomics partner with Eisai’s new

Currently, the company has multiple Phase III trials underway evaluating ADS-5102 for this indication, which currently has no FDA-approved treatment options. ADS-5102 (amantadine HCl) is a high dose,

At the new facility, the company will produce both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market. Located in Technopark Grabtsevo in the Kaluga

The company’s US unit Eisai employs about 1,800 people and its operations include research and development, manufacturing, sales and marketing and administrative functions. Eisai chairman and CEO Yuji

The company’s lead compound, cabozantinib, inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. Currently, cabozantinib is being evaluated in an ongoing Phase III METEOR

The deal is part of Cipla’s front-end strategy and will expedite its product registrations in Brazil. Subject to certain closing deliverables, the transaction is expected to be completed

The trial showed that WM patients treated with Imbruvica experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of

Development of the LIMITX is currently being supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to develop an

If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of the disease. Lifitegrast is a new small-molecule integrin inhibitor